At the news
? NEUTRALIMPACT 2/10 144 filed Nov 12, 2026 at 16:23 ET
Director Martine Zimmermann filed a Form 144 notice of intent to sell 2,000 shares of Ligand Pharmaceuticals common stock, with an estimated aggregate market value of approximately $636,336. The shares were acquired through restricted stock grants in 2025 and 2026. This is a routine insider sale by a director and represents a small fraction of the company's market cap.
- Reporting person: Martine Zimmermann, Director of Ligand Pharmaceuticals
- Securities to be sold: 2,000 shares of Common Stock
- Estimated aggregate market value: $636,336.20
- Shares acquired via restricted stock grants on 06/06/2025 (626 shares), 09/22/2025 (647 shares), and 06/05/2026 (727 shares)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access